Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Samuel Kintz currently holds 890,392 shares of Enliven Therapeutics, Inc. (ELVN), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Samuel Kintz has been a net seller of ELVN stock. They have purchased $0 and sold $4.9M worth of shares.
Samuel Kintz's most recent insider trade was on Nov 17, 2025, when they sold 12,500 shares at $21.82 per share.
Samuel Kintz serves as Executive at Enliven Therapeutics, Inc. (ELVN). They have executed 55 insider transactions totaling $4.9M over their tenure at the company.
Samuel Kintz holds the position of Executive at Enliven Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 3 years and currently hold a stake valued at $0.
Samuel Kintz has shown a selling trading pattern, with $0 in total purchases and $4.9M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Samuel Kintz was on Apr 11, 2024, when they sold $1.2M worth of ELVN shares. This transaction involved 47,709 shares at $25.04 per share.
Samuel Kintz currently owns 890,392 shares of Enliven Therapeutics, Inc. (ELVN), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Samuel Kintz's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Samuel Kintz has 55 Form 4 filings on record as an insider at Enliven Therapeutics, Inc..
Set alerts for Samuel Kintz and 40,000+ other insiders.